EOCN Stock Forecast: Eocene Ltd. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.78
+1.73% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 11 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$1.9M
Ticker Nerd rank
11/ 100
Median analyst target
—
Analysts covering
1
Revenue$0.0
Operating income−$2.8M
Net income−$2.7M
Free cash flow−$2.1M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−28.2%
1M
−42.0%
YTD
−70.4%
1Y
−72.7%
From 52W high
−81.6%
From 52W low
+1.7%
$1.75
$9.68
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Eocene Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
11/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
54
Quality
33
Volatility
26
Growth
24
Revisions
20
Issuance
16
Value
12
Momentum
9

Accruals (54): Reported profit is backed by cash, and the company is not expanding recklessly.

Momentum (9): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

EOCN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on EOCN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00Jan 26Apr 26Jul 26Oct 26EOCN

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0
Buy
1
Hold
0
Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
4 Apr 2025Maxim GroupDowngradeHold—
24 July 2023Maxim GroupUpgradeBuy—
8 Aug 2022Canaccord GenuityDowngradeHold—
8 Aug 2022Maxim GroupDowngradeHold—
18 May 2022Raymond JamesDowngradeMarket Perform—
3 May 2022HC Wainwright & Co.DowngradeNeutral—
3 May 2022Raymond JamesMaintainsOutperform—
17 May 2021Canaccord GenuityMaintainsBuy—
19 Mar 2021HC Wainwright & Co.MaintainsBuy—
8 Jan 2021Raymond JamesMaintainsOutperform—
25 Nov 2020Canaccord GenuityMaintainsBuy—
22 May 2020B. Riley FBRDowngradeNeutral—
22 May 2020B. Riley SecuritiesDowngradeNeutral—
15 May 2020Raymond JamesMaintainsOutperform—
13 Mar 2020B. Riley FBRMaintainsBuy—
13 Mar 2020B. Riley SecuritiesMaintainsBuy—
13 Mar 2020StifelMaintainsBuy—
4 Feb 2020Craig-HallumInitiatesBuy—
30 Jan 2020Cantor FitzgeraldAssumesOverweight$59 → $14
22 July 2019Laidlaw & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for EOCN.

Market Radar

This page is one stock. Monday covers all of them.

EOCN appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

EOCN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Eocene Ltd. returned −72.7% against +6.9% for the S&P 500, dividends included.

EOCN vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120140Jan 26Apr 26Jul 26Oct 26EOCNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

EOCN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
0.1×

Cheaper than 95% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−68.2%

Higher than 18% of US stocks

Return on assets
−30.2%

Higher than 14% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Eocene Ltd. has a market value of $1.9M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$11.3M.

  • Free cash flow in the twelve months to 30 June 2026: −$8.5M.

  • Shares outstanding: 1.1M.

  • Eocene Ltd. employs 3 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

EOCN and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
EOCNEocene Ltd.$1.9M11
PPCBPropanc Biopharma, Inc.$1.8M45
XRTXXORTX Therapeutics, Inc.$1.9M11
GNPXGenprex, Inc.$1.9M10
KALAKala Bio, Inc.$1.7M15
DCOYDecoy Therapeutics, Inc.$2.0M15
KAPAKairos Pharma Ltd.$2.0M35

Take a look at EOCN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Eocene Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about EOCN

Is EOCN stock a buy right now?

Of the 1 analyst covering Eocene Ltd., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Eocene Ltd. 11 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank EOCN?

As at 21 Nov 2026, Eocene Ltd. ranks 11 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (54 of 100).

What is the EOCN stock forecast for 2030?

No analyst covering Eocene Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for EOCN are extrapolating price history, which says nothing about the business.

How has EOCN stock performed over the past year?

Eocene Ltd. returned -72.7% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Eocene Ltd. do?

Eocene Ltd. is an Israel-based biopharmaceutical and medtech company focused on gastrointestinal disease management and related therapeutic areas. The company develops pharmaceutical and device-based solutions for conditions such as liver disorders, gastrointestinal oncology, and colorectal care.

Company

About Eocene Ltd.

Eocene Ltd. is an Israel-based biopharmaceutical and medtech company focused on gastrointestinal disease management and related therapeutic areas. The company develops pharmaceutical and device-based solutions for conditions such as liver disorders, gastrointestinal oncology, and colorectal care. Its portfolio includes Aramchol, an oral therapeutic candidate being developed for liver-related indications, as well as medical device technologies designed to support postoperative colorectal treatment. Eocene Ltd. combines research, clinical development, and product commercialization activities across its healthcare platform, with operations centered in Ramat Gan, Israel. The company serves a niche role in the biotechnology market by pursuing therapies and technologies aimed at unmet needs in gastrointestinal and adjacent medical fields.

CEO Mr. Allen Baharaff · 3 employees · Israel · https://eocn.com